{"product_id":"jnj-ansoff-analysis","title":"(JNJ) Johnson \u0026 Johnson ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Growth Paths Behind the Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Johnson \u0026amp; Johnson Ansoff Matrix Analysis helps you quickly assess growth options across market penetration, market development, product development, and diversification in a clear, actionable format; the page includes a real preview\/sample of the analysis so you can judge style and substance before buying—purchase the full version to receive the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDARZALEX myeloma share defense\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDarzalex is Johnson \u0026amp; Johnson’s lead multiple myeloma brand, and it keeps defending share by pushing deeper into the same oncology base. In FY2025, it stayed a near $13 billion product, showing how strong prescriber loyalty and hospital access can hold a mature asset. The play is simple: use approved regimens to treat more patients, not to chase a new market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTREMFYA psoriasis and PsA growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTremfya is already a core psoriasis and psoriatic arthritis brand for Johnson \u0026amp; Johnson, so market penetration means taking more share in the same immunology pool. In 2024, Tremfya generated about $3.67 billion in sales, showing strong use in specialist care. J\u0026amp;J is focused on deeper prescriber reach and payer access to keep patients on Tremfya instead of rival biologics like IL-17 and other IL-23 drugs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eERLEADA prostate cancer expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eERLEADA is Johnson \u0026amp; Johnson’s existing prostate-cancer therapy, so this is market penetration, not a new therapeutic bet. Janssen reported ERLEADA sales of about $2.2 billion in 2024, showing strong uptake in the same disease market. The move is to win more use from oncologists and urologists, and grow share without changing the core cancer segment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eACUVUE contact lens retention\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eACUVUE retention in Johnson \u0026amp; Johnson’s Ansoff matrix is a market-penetration play: keep existing wearers buying in the same retail and eye-care channels, then lift share through repeat orders and loyalty. The brand’s daily, 2-week, and monthly replacement cycles create built-in re-purchase points, so retention is driven by fit, comfort, and doctor recommendation rather than one-off sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRepeat-buy model, not new-market expansion\u003c\/li\u003e\n\u003cli\u003eSame channels: optometrists and retail\u003c\/li\u003e\n\u003cli\u003eShort replacement cycles support loyalty\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDePuy Synthes and Ethicon account share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDePuy Synthes and Ethicon both sell into the same hospital operating room base, so Johnson \u0026amp; Johnson can lift share by cross-selling implants, surgical tools, and wound-closure products to the same accounts. In 2025, Johnson \u0026amp; Johnson's MedTech unit was a roughly $30B-plus business, so even a small share gain in large hospital systems can move revenue. This is account penetration, not new-market entry.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame hospital accounts\u003c\/li\u003e\n\u003cli\u003eCross-sell within current buyers\u003c\/li\u003e\n\u003cli\u003eShare gain, not market entry\u003c\/li\u003e\n\u003cli\u003eHigher wallet share in surgery\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJ\u0026amp;J Grows by Winning More Share from the Same Customers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJohnson \u0026amp; Johnsons market penetration is about taking more share from the same buyers, not opening new ones. In FY2025, Darzalex stayed near $13 billion, ERLEADA was about $2.6 billion, and Tremfya kept scaling in the same immunology pool. ACUVUE and MedTech do the same in eye care and hospitals by driving repeat use and account share.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003eFY2025 sales\u003c\/th\u003e\n\u003cth\u003ePenetration lever\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDarzalex\u003c\/td\u003e\n\u003ctd\u003e~$13B\u003c\/td\u003e\n\u003ctd\u003eMore use in myeloma\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eERLEADA\u003c\/td\u003e\n\u003ctd\u003e~$2.6B\u003c\/td\u003e\n\u003ctd\u003eMore share in prostate cancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTremfya\u003c\/td\u003e\n\u003ctd\u003e~$4B\u003c\/td\u003e\n\u003ctd\u003eDeeper specialist adoption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Ansoff Matrix overview of Johnson \u0026amp; Johnson’s growth strategy across existing and new products and markets\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eHelps Johnson \u0026amp; Johnson quickly clarify growth options and reduce strategic planning friction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, vetted source list tying each Ansoff growth path for Johnson \u0026amp; Johnson to traceable, reputable references for faster, defensible strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOutpatient orthopaedics adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDePuy Synthes can extend its knee, hip, and trauma implants from inpatient hospitals into ambulatory surgery centers, a clear market development move into a new care setting for the same products. This fits the shift to lower-acuity care: U.S. outpatient joint replacement volumes have risen sharply, with Medicare adding more procedures to the ASC list in 2025. For Johnson \u0026amp; Johnson, that widens access without changing the core implant platform.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCardiac ablation lab expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJohnson \u0026amp; Johnson can sell the same electrophysiology tools into more cardiac ablation labs as procedure use widens beyond major centers. In 2024, FDA-approved pulsed field ablation made adoption easier, and AFib affects about 59 million people worldwide, supporting more lab volume. This is market development: same product set, bigger customer base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStroke-center neurovascular reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJohnson \u0026amp; Johnson can grow Cerenovus by placing the same neurovascular devices in more stroke centers and intervention networks, so this is market development, not product change. Stroke is still a huge need: the World Stroke Organization estimates 12.2 million new strokes each year, and about 87% are ischemic. More sites mean faster access and a bigger installed base for current MedTech products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRetail eye-care channel growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eACUVUE can grow by widening placement in optometry and retail eye-care chains, while the product stays the same. Johnson \u0026amp; Johnson reported $88.8 billion in 2024 sales, so even a small channel mix shift can add scale fast.\u003c\/p\u003e\n\u003cp\u003eMore local and national distributors also help ACUVUE reach new geographies and store formats. That is classic market development: same lens, wider access, more shelf presence, and more exams that convert into repeat sales.\u003c\/p\u003e\n\u003cp\u003eKey points:\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpand through optometry networks\u003c\/li\u003e\n\u003cli\u003eAdd retail eye-care channels\u003c\/li\u003e\n\u003cli\u003eUse existing ACUVUE products\u003c\/li\u003e\n\u003cli\u003eReach new geographies faster\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGlobal oncology access buildout\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJohnson \u0026amp; Johnson can drive market development by taking existing Innovative Medicine brands into more countries and payer systems, expanding access without needing new drugs. In 2024, Innovative Medicine sales reached $57.5 billion, showing the scale of its global base for oncology and immunology growth. This fits a geographic expansion play, with current products like Darzalex and Tremfya used across more healthcare systems.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUse existing brands in new markets.\u003c\/li\u003e\n\u003cli\u003eExpand payer access and reimbursement.\u003c\/li\u003e\n\u003cli\u003eScale oncology and immunology globally.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJ\u0026amp;J’s Growth Engine: More Care Settings, More Channels, More Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJohnson \u0026amp; Johnson can grow by taking existing devices and brands into new care settings, channels, and geographies. The clearest plays are DePuy Synthes in ambulatory surgery centers, ACUVUE in retail eye care, and Innovative Medicine in more countries and payer systems.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eASC shift\u003c\/td\u003e\n\u003ctd\u003eMore outpatient joint cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEye care channels\u003c\/td\u003e\n\u003ctd\u003e2024 sales: $88.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal expansion\u003c\/td\u003e\n\u003ctd\u003eInnovative Medicine: $57.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eJohnson \u0026amp; Johnson Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVARIPULSE atrial fibrillation system\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVARIPULSE adds J\u0026amp;J MedTech a pulsed-field ablation platform for the same atrial-fibrillation market, so this is product development in Ansoff terms. AF affects about 59.7 million people worldwide, and J\u0026amp;J can sell a new technology to an existing base. That fits electrophysiology portfolio expansion without changing the core customer.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRYBREVANT and LAZCLUZE regimen\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRYBREVANT plus LAZCLUZE expanded Johnson \u0026amp; Johnson’s oncology toolkit for EGFR-mutated NSCLC, a familiar market with a new product mix. In MARIPOSA, the combo cut the risk of progression or death by 30% versus osimertinib and lifted median progression-free survival to 23.7 months from 16.6 months. That gives existing lung-cancer patients a fresh first-line option.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTREMFYA ulcerative colitis launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTREMFYA’s ulcerative colitis FDA approval in September 2024 added a new use to an existing biologic, so Johnson \u0026amp; Johnson can sell the same molecule through its established immunology sales force and payer network. That is classic product development in the Ansoff Matrix: new product use, same core market. The move also widens TREMFYA’s addressable inflammatory-bowel-disease market beyond psoriasis and psoriatic arthritis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCARVYKTI earlier-line myeloma use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCARVYKTI moved from later relapsed disease into earlier multiple-myeloma use, so Johnson \u0026amp; Johnson kept the same oncology market but added a new use case. In 2025, CARVYKTI remained the first BCMA CAR-T with earlier-line uptake, and J\u0026amp;J said it passed $1 billion in annual sales run-rate, showing stronger pull from the same specialist base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket penetration: same myeloma niche\u003c\/li\u003e\n\u003cli\u003eNew use case: earlier-line label expansion\u003c\/li\u003e\n\u003cli\u003eSame buyers: hematology-oncology specialists\u003c\/li\u003e\n\u003cli\u003eHigher value: broader patient pool\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eACUVUE OASYS MAX 1-Day line\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eACUVUE OASYS MAX 1-Day widened Johnson \u0026amp; Johnson Vision Care’s lens mix by adding a daily-disposable option for existing wearers, a clear product development move in the Ansoff Matrix. The line builds on the ACUVUE OASYS platform and targets the large daily lens segment, which remains one of the fastest-used formats in eye care.\u003c\/p\u003e\n\u003cp\u003eIt helps Johnson \u0026amp; Johnson defend share with current eye-care customers while raising switching costs through a fuller product ladder. This is new product introduction into an established market, not a new-market bet.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpands the lens lineup\u003c\/li\u003e\n\u003cli\u003eAdds a daily-disposable choice\u003c\/li\u003e\n\u003cli\u003eTargets current eye-care users\u003c\/li\u003e\n\u003cli\u003eFits product development strategy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJ\u0026amp;J Expands Winners With New Uses and New Formats\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJohnson \u0026amp; Johnson’s product development play is adding new uses and new formats for existing buyers: TREMFYA in ulcerative colitis, CARVYKTI in earlier myeloma, and VARIPULSE in atrial fibrillation. That keeps the same specialist and payer base while widening the product stack. In 2025, CARVYKTI topped a $1 billion annual sales run-rate, signaling real pull.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2025 signal\u003c\/th\u003e\n\u003cth\u003eAnsoff fit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCARVYKTI\u003c\/td\u003e\n\u003ctd\u003e$1B+ run-rate\u003c\/td\u003e\n\u003ctd\u003eNew use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTREMFYA\u003c\/td\u003e\n\u003ctd\u003eUC expansion\u003c\/td\u003e\n\u003ctd\u003eNew indication\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVARIPULSE\u003c\/td\u003e\n\u003ctd\u003ePFA platform\u003c\/td\u003e\n\u003ctd\u003eNew product\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAbiomed Impella heart recovery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAbiomed gave Johnson \u0026amp; Johnson entry into mechanical circulatory support, broadening it beyond its legacy pharma core. The $16.6 billion deal added Impella, a catheter-based pump used in high-risk PCI and heart-failure care, two markets Johnson \u0026amp; Johnson had not served before. That made the move a clear diversification play: a new product category, a new cardiovascular use case, and a new revenue stream.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eShockwave intravascular lithotripsy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJohnson \u0026amp; Johnson’s 2024 $13.1 billion Shockwave Medical deal added intravascular lithotripsy to its cardiovascular portfolio, opening a new intervention platform. Shockwave treats calcified coronary and peripheral arteries, a distinct market from J\u0026amp;J’s core stents and structural-heart tools. In 2025, this diversification matters because it gives J\u0026amp;J access to a high-growth, procedure-driven segment with recurring hospital use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eV-Wave structural heart therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJ\u0026amp;J agreed in 2024 to acquire V-Wave, a move into structural heart therapy via an interatrial shunt for heart-failure patients. This is a new product in a new adjacent market, so it fits Ansoff diversification. Heart failure affects about 64 million people worldwide, and J\u0026amp;J’s MedTech unit reported 2025 sales of about $30.8 billion, giving it scale to push the platform.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMonarch robotic bronchoscopy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMonarch robotic bronchoscopy gave Johnson \u0026amp; Johnson a foothold in pulmonary diagnostics and intervention, moving MedTech beyond drugs and into a new procedure category. J\u0026amp;J bought Auris Health for $3.4B in 2019, and by FY2025 its MedTech sales were about $31B, showing why diversification into robotic care mattered.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEntered robotic bronchoscopy.\u003c\/li\u003e\n\u003cli\u003eExpanded beyond drug markets.\u003c\/li\u003e\n\u003cli\u003eBuilt MedTech procedure breadth.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCARVYKTI cell therapy platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCARVYKTI, co-developed with Legend Biotech, moved Johnson \u0026amp; Johnson into CAR-T cell therapy, a new modality beyond small-molecule drugs. In 2024, CARVYKTI net sales reached about $963 million, up sharply year over year, showing real traction in advanced oncology. This diversification widens Johnson \u0026amp; Johnson's presence in hematologic cancer care and adds a higher-value, science-led growth lane.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew modality: CAR-T therapy\u003c\/li\u003e\n\u003cli\u003e2024 sales: about $963 million\u003c\/li\u003e\n\u003cli\u003eExpands into multiple myeloma care\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJ\u0026amp;J’s 2025 MedTech Push Expands Its Growth Engine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDiversification is clear in Johnson \u0026amp; Johnson’s 2025 MedTech push: Abiomed, Shockwave Medical, V-Wave, and Monarch moved it into mechanical support, lithotripsy, structural heart, and robotic bronchoscopy. FY2025 MedTech sales were about $31 billion, showing scale behind the shift. CARVYKTI also broadened J\u0026amp;J into CAR-T oncology.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003e2025 value\u003c\/th\u003e\n\u003cth\u003eWhy it fits diversification\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAbiomed\u003c\/td\u003e\n\u003ctd\u003e$16.6B deal\u003c\/td\u003e\n\u003ctd\u003eNew cardiovascular platform\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShockwave\u003c\/td\u003e\n\u003ctd\u003e$13.1B deal\u003c\/td\u003e\n\u003ctd\u003eNew procedure category\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedTech\u003c\/td\u003e\n\u003ctd\u003e~$31B sales\u003c\/td\u003e\n\u003ctd\u003eFunds broader expansion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57191845855497,"sku":"jnj-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/jnj-ansoff-analysis.webp?v=1783678784","url":"https:\/\/dcfanalyst.com\/products\/jnj-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}